Rockefeller Capital Management L.P. Buys 441,154 Shares of Solana Company $HSDT

Rockefeller Capital Management L.P. raised its stake in Solana Company (NASDAQ:HSDT) by 11,764.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 444,904 shares of the company’s stock after buying an additional 441,154 shares during the period. Rockefeller Capital Management L.P. owned 1.08% of Solana worth $1,286,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Aristides Capital LLC bought a new position in shares of Solana in the 4th quarter valued at $137,000. XTX Topco Ltd bought a new stake in Solana during the 4th quarter worth $140,000. Arrington Capital Management LLC acquired a new position in Solana in the 4th quarter worth about $1,904,000. Cetera Investment Advisers acquired a new position in Solana in the 4th quarter worth about $347,000. Finally, Price T Rowe Associates Inc. MD bought a new position in Solana in the fourth quarter valued at about $46,000. Institutional investors own 18.63% of the company’s stock.

Solana Trading Up 5.5%

NASDAQ HSDT opened at $1.74 on Thursday. The firm has a market capitalization of $101.60 million, a PE ratio of -0.02 and a beta of 1.03. The business’s 50-day moving average price is $1.89 and its two-hundred day moving average price is $2.25. Solana Company has a 12 month low of $1.19 and a 12 month high of $25.50.

Solana (NASDAQ:HSDT) last issued its quarterly earnings data on Friday, May 15th. The company reported ($1.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.96). The company had revenue of $3.62 million for the quarter, compared to the consensus estimate of $3.40 million. Solana had a negative return on equity of 67.57% and a negative net margin of 1,427.15%. As a group, analysts forecast that Solana Company will post -0.09 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently weighed in on HSDT. Maxim Group started coverage on Solana in a report on Monday, April 6th. They set a “buy” rating and a $4.00 price target on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Solana in a report on Tuesday, April 21st. B. Riley Financial initiated coverage on shares of Solana in a research report on Thursday, April 23rd. They set a “buy” rating and a $3.00 target price on the stock. Finally, Zacks Research raised shares of Solana to a “hold” rating in a report on Monday, April 27th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $3.50.

Solana Profile

Helius Medical Technologies, Inc (NASDAQ: HSDT) is a medical technology company focused on developing and commercializing non‐invasive neuromodulation platforms designed to enhance neurorehabilitation. Its flagship product, the Portable Neuromodulation Stimulator (PoNS®), delivers mild electrical pulses to the tongue to stimulate neural pathways in conjunction with targeted physical therapy. The device is intended to improve neuroplasticity and support recovery in patients with neurological conditions.

The PoNS system is cleared for use in the United States, Canada and the European Union and is prescribed through specialized rehabilitation clinics.